abstract
OBJECTIVE:
This
study aimed to assess the role and complications of extensive
cytoreduction with
PlasmaJet (Plasma Surgical, Roswell, Ga) in ovarian
cancer with peritoneal carcinomatosis.
MATERIALS:
All
patients undergoing primary, secondary, or interval debulking surgery
for ovarian cancer and treated with PlasmaJet between October 2013 and
February 2015 were analyzed.
RESULTS:
Nineteen
patients were enrolled. The median operative time was 270 minutes,
median blood loss was 700 mL, and median length of stay was 9 days. In
all patients, complete resection of all macroscopic disease was
achieved.We used PlasmaJet to remove peritoneal carcinomatosis on the
abdominal peritoneum, intestinal mesentery, bowel serosa, and
diaphragmatic region. Overall, we treated 66 organs with PlasmaJet in
our series. No bowel or urological fistulas were observed. According to
the Clavien-Dindo classification, 13 adverse events were recorded at
grade 2 or lesser. We observed only 1 grade 3 adverse event. No
postoperative mortality was recorded.
CONCLUSIONS:
In
our series, the PlasmaJet seems to be an efficient device for tumor
ablation or dissection to obtain complete resection of all macroscopic
disease in patients with peritoneal carcinomatosis.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.